The European Medicines Agency EMA has started the test procedure for a new corona drug.
The Swedish-British manufacturer Astrazeneca developed the combination preparation Evusheld, which is intended to prevent adults from becoming sick with Covid-19, as the EMA announced on Thursday in Amsterdam.
Initial test results indicated that the agent was effective in protecting against the disease.
The experts now continuously evaluate data from tests and weigh the advantages and disadvantages of the preparation against each other.
It is not known when a final result will be available.
According to the authority, the manufacturer has not yet submitted an application for approval on the European market.
The drug consists of the active ingredients tixagevimab and cilgavimab.
So far, only the drug Remdesivir has been approved as a special corona drug in the EU.
Approval procedures are currently underway for five preparations.
A total of three agents are currently still being examined by the experts.